CVS Health reported second-quarter 2026 adjusted earnings per share of $2.58, up 42.5% year over year and beating the Zacks Consensus Estimate by 37.97%, while revenues rose 7.3% to $106.10 billion, surpassing expectations by 5.91%. The company raised its full-year 2026 adjusted earnings guidance to $7.90-$8.10 per share from $7.30-$7.50, and lifted its revenue outlook to at least $414 billion from at least $405 billion. Management also increased its cash flow from operations forecast to at least $11.5 billion from at least $9.5 billion, citing improved expectations for the Health Care Benefits and Pharmacy & Consumer Wellness segments. Since the earnings report, shares have gained about 1%, outperforming the S&P 500, but estimates have trended downward by 6.08% over the past month. CVS Health holds a Zacks Rank #3 (Hold) with a VGM Score of A.
CVS Health CorpCVS beat Q2 estimates and raised full-year guidance, boosting earnings outlook.
ICON PLC